Nonacog beta pegol 500unit powder and solvent for solution for injection vials
Requires a prescription from a doctor or prescriber
Nonacog beta pegol is a recombinant coagulation factor IX derivative.
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Nonacog beta pegol
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Nonacog beta pegol
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
MHRA licensed products
View all licensed products for Nonacog beta pegol on the MHRA register
Refixia 500unit powder and solvent for solution for injection vials
Therapeutically similar medicines
Similarity based on WHO Anatomical Therapeutic Chemical (ATC) classification and NHS BNF section grouping. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
Clinical guidelines and formulary information
British National Formulary
Nonacog beta pegol
Source: British National Formulary, NICE. Joint Formulary Committee. Contains public sector information licensed under the Open Government Licence v3.0.
NICE clinical guidance(1)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & product information
Official product databases and supply status monitoring
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. emc (electronic medicines compendium) is operated by Datapharm Ltd. Shortage information sourced from NHS Specialist Pharmacy Service (SPS), sps.nhs.uk.
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF codes from NHS Business Services Authority (NHSBSA). ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
70 to 89 hours
Mechanism
Nonacog beta pegol is activated by factor IXa and the tissue complex factor VII,…
Food interactions
None known
Human targets
3 targets
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
[L43682]…
Half-life
70 to 89 hours
[L43682]
Protein binding
[L1103]
Volume of distribution
72 ml
Metabolism
[A31501]…
Elimination
40%
[A31502]…
Clearance
0.4 to 0.8 mL
[L43682]
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
[L41175][L41180][L41185][L43682]
It is also used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes.
[L41180][L43682]
Known interactions with other medications. Always consult a healthcare professional.
Showing 50 of 128 interactions
How the body processes this drug — absorption, distribution, metabolism, and elimination
[L43682]
In preclinical studies, there was a reduced accumulation of systemic drug after multiple dosing.
[L1103]
[L43682]
[L1103]
[L1099]
At steady state, the volume of distribution of nonacog beta pegol is 64 ml/kg.
[L1099]
Nonacog beta pegol is not expected to accumulate in tissues.
[A31502]
[A31501]
The PEG component of the drug is retained in the body 7.5 to 9 times longer than the original compound, as it is returned to circulation.
[L1100]
[A31502]
The PEG part of the drug seems to be eliminated with a bi-phasic profile that was registered at 2-3 days and at 15-18 days.
[L1103]
[L43682]
Proteins and enzymes this drug interacts with in the body
In the presence of tissue factor and calcium ions, factor VIIa then converts factor X to factor Xa by limited proteolysis. Factor VIIa also converts factor IX to factor IXa in the presence of tissue factor and calcium PMID:271951
PMID:22409427
Factor Xa activates pro-inflammatory signaling pathways in a protease-activated receptor (PAR)-dependent manner .
PMID:24041930 PMID:30568593 PMID:34831181 PMID:18202198
Up-regulates expression of protease-activated receptors (PARs) F2R, F2RL1 and F2RL2 in dermal microvascular endothelial cells .
PMID:35738824
Triggers the production of pro-inflammatory cytokines, such as MCP-1/CCL2 and IL6, in cardiac fibroblasts and umbilical vein endothelial cells in PAR-1/F2R-dependent manner .
PMID:30568593 PMID:34831181
Triggers the production of pro-inflammatory cytokines, such as MCP-1/CCL2, IL6, TNF-alpha/TNF, IL-1beta/IL1B, IL8/CXCL8 and IL18, in endothelial cells and atrial tissues .
PMID:24041930 PMID:35738824 PMID:9780208
Induces expression of adhesion molecules, such as ICAM1, VCAM1 and SELE, in endothelial cells and atrial tissues .
PMID:24041930 PMID:35738824 PMID:9780208
Increases expression of phosphorylated ERK1/2 in dermal microvascular endothelial cells and atrial tissues .
PMID:24041930 PMID:35738824
Triggers activation of the transcription factor NF-kappa-B in dermal microvascular endothelial cells and atrial tissues .
PMID:24041930 PMID:35738824
Activates pro-inflammatory and pro-fibrotic responses in dermal fibroblasts and enhances wound healing probably via PAR-2/F2RL1-dependent mechanism .
PMID:18202198
Activates barrier protective signaling responses in endothelial cells in PAR-2/F2RL1-dependent manner; the activity depends on the cleavage of PAR-2/F2RL1 by factor Xa .
PMID:22409427
Up-regulates expression of plasminogen activator inhibitor 1 (SERPINE1) in atrial tissues PMID:24041930
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Nonacog beta pegol
Additional database identifiers
Drugs Product Database (DPD)
22916
HUGO Gene Nomenclature Committee (HGNC)
HGNC:3544
GenAtlas
F7
GeneCards
F7
GenBank Gene Database
M13232
GenBank Protein Database
182801
Guide to Pharmacology
2363
UniProt Accession
FA7_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:3546
GenAtlas
F8
GeneCards
F8
GenBank Gene Database
M14113
GenBank Protein Database
182818
UniProt Accession
FA8_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:3528
GenAtlas
F10
GeneCards
F10
GenBank Gene Database
K03194
GenBank Protein Database
182841
Guide to Pharmacology
2359
UniProt Accession
FA10_HUMAN
DrugBank citations
If you use DrugBank data in your research, please cite the following publications: